Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 5;11(12):1035. doi: 10.1038/s41419-020-03241-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Med8A-S and DAOY cells were treated with vincristine at the indicated concentrations for 48 h, and cell viability assessed by measuring the fluorescence after incubation with CellTiter-Blue (CTB) for 4 h. As plotted is the mean ± SD of an experiment performed in triplicates, representative of at least 3 independent experiments. b Schematic for derivation of drug resistant Med8A cells. The chemosensitive parental cell line, Med8A-S, was subjected to incremental selection in vincristine over a period of 4 months to derive the stable chemoresistant variant Med8A-R. The endpoint vincristine concentration was at 0.16 μg/mL. Med8A-S and Med8A-R were treated with (c) vincristine (d) cisplatin (e) mitoxantrone and (f) idarubicin for 48 h and cell viability assessed with CTB. The data represent the mean ± SD of three replicates; ***p < 0.001, two-way ANOVA with Bonferroni’s multiple comparison test.